Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Entire DC Network
Outcomes Associated With Sars-Cov-2 Reinfection In Individuals With Natural And Hybrid Immunity, Geehan Suleyman, Raef Fadel, Kunj Patel, Al Muthanna Shadid, Haim Bernardo Cotlear Stuart, Michael Kattula, Andrea Janis, Mohamed Maki, Shing Chao, George Alangaden, Indira Brar
Outcomes Associated With Sars-Cov-2 Reinfection In Individuals With Natural And Hybrid Immunity, Geehan Suleyman, Raef Fadel, Kunj Patel, Al Muthanna Shadid, Haim Bernardo Cotlear Stuart, Michael Kattula, Andrea Janis, Mohamed Maki, Shing Chao, George Alangaden, Indira Brar
Infectious Diseases Articles
BACKGROUND: Studies comparing SARS-CoV-2 reinfection outcomes among individuals with previous infection (natural immunity) and previous infection plus vaccination (hybrid immunity) are limited.
METHODS: Retrospective cohort study comparing SARS-CoV-2 reinfection among patients with hybrid immunity (cases) and natural immunity (controls) from March 2020 to February 2022. Reinfection was defined as positive PCR> 90 days after initial laboratory-confirmed SARS-CoV-2 infection. Outcomes included time to reinfection, symptom severity, COVID-19-related hospitalization, critical COVID-19 illness (need for intensive care unit, invasive mechanical ventilation, or death), length of stay (LOS).
RESULTS: A total of 773 (42%) vaccinated and 1073 (58%) unvaccinated patients with reinfection were included. …
Safety And Tolerability Of Ser-109 As An Investigational Microbiome Therapeutic In Adults With Recurrent Clostridioides Difficile Infection: A Phase 3, Open-Label, Single-Arm Trial, Matthew D. Sims, Sahil Khanna, Paul Feuerstadt, Thomas J. Louie, Colleen R. Kelly, Edward S. Huang, Elizabeth L. Hohmann, Elaine E. L Wang, Caterina Oneto, Stuart H. Cohen, Charles S. Berenson, Louis Korman, Christine Lee, Bret Lashner, Colleen S. Kraft, Mayur Ramesh, Michael Silverman, Darrell S. Pardi, Ananya De, Asli Memisoglu, David A. Lombardi, Brooke R. Hasson, Barbara H. Mcgovern, Lisa Von Moltke
Safety And Tolerability Of Ser-109 As An Investigational Microbiome Therapeutic In Adults With Recurrent Clostridioides Difficile Infection: A Phase 3, Open-Label, Single-Arm Trial, Matthew D. Sims, Sahil Khanna, Paul Feuerstadt, Thomas J. Louie, Colleen R. Kelly, Edward S. Huang, Elizabeth L. Hohmann, Elaine E. L Wang, Caterina Oneto, Stuart H. Cohen, Charles S. Berenson, Louis Korman, Christine Lee, Bret Lashner, Colleen S. Kraft, Mayur Ramesh, Michael Silverman, Darrell S. Pardi, Ananya De, Asli Memisoglu, David A. Lombardi, Brooke R. Hasson, Barbara H. Mcgovern, Lisa Von Moltke
Infectious Diseases Articles
IMPORTANCE: A safe and effective treatment for recurrent Clostridioides difficile infection (CDI) is urgently needed. Antibiotics kill toxin-producing bacteria but do not repair the disrupted microbiome, which promotes spore germination and infection recurrence.
OBJECTIVES: To evaluate the safety and rate of CDI recurrence after administration of investigational microbiome therapeutic SER-109 through 24 weeks.
DESIGN, SETTING, AND PARTICIPANTS: This phase 3, single-arm, open-label trial (ECOSPOR IV) was conducted at 72 US and Canadian outpatient sites from October 2017 to April 2022. Adults aged 18 years or older with recurrent CDI were enrolled in 2 cohorts: (1) rollover patients from the ECOSPOR …